Genetic variability in CYP2A6 and the pharmacokinetics of nicotine
- PMID: 17979512
- DOI: 10.2217/14622416.8.10.1385
Genetic variability in CYP2A6 and the pharmacokinetics of nicotine
Abstract
Nicotine is the psychoactive substance responsible for tobacco dependence. It is also a therapeutic used to aid smoking cessation. Cytochrome P450 (CYP)2A6 is the human hepatic enzyme that mediates most of nicotine's metabolic inactivation to cotinine. Genetic variation in the CYP2A6 gene can increase or decrease enzyme activity through altering the protein's expression level or its structure and function. This article reviews CYP2A6 genetic variation and its impact on in vivo nicotine kinetics, including a description of the individual variants, different phenotyping approaches for assessing in vivo CYP2A6 activity and other sources of variation in nicotine metabolism such as gender. In addition, the effect of CYP2A6 polymorphisms on smoking behavior and tobacco-related lung cancer risk are briefly described. Furthering knowledge in this area will improve interpretation of studies examining smoking behavior, as well as those using nicotine as a therapeutic agent.
Similar articles
-
Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.Clin Pharmacol Ther. 2005 Mar;77(3):145-58. doi: 10.1016/j.clpt.2004.10.011. Clin Pharmacol Ther. 2005. PMID: 15735609 Review.
-
CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.Clin Pharmacol Ther. 2006 Nov;80(5):457-67. doi: 10.1016/j.clpt.2006.08.011. Clin Pharmacol Ther. 2006. PMID: 17112802 Clinical Trial.
-
Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior.Ther Drug Monit. 2002 Feb;24(1):163-71. doi: 10.1097/00007691-200202000-00026. Ther Drug Monit. 2002. PMID: 11805739 Review.
-
Smoking behavior and related cancers: the role of CYP2A6 polymorphisms.Curr Opin Mol Ther. 2007 Dec;9(6):538-44. Curr Opin Mol Ther. 2007. PMID: 18041664 Review.
-
Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6.Drug Metab Rev. 2002 Nov;34(4):865-77. doi: 10.1081/dmr-120015696. Drug Metab Rev. 2002. PMID: 12487152 Review.
Cited by
-
CYP2A6 genetic polymorphisms and biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the Singapore Chinese Health Study.Carcinogenesis. 2017 Apr 1;38(4):411-418. doi: 10.1093/carcin/bgx012. Carcinogenesis. 2017. PMID: 28182203 Free PMC article.
-
Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6.Chem Res Toxicol. 2017 Jan 17;30(1):410-419. doi: 10.1021/acs.chemrestox.6b00387. Epub 2016 Nov 22. Chem Res Toxicol. 2017. PMID: 28092945 Free PMC article.
-
Reconciling human smoking behavior and machine smoking patterns: implications for understanding smoking behavior and the impact on laboratory studies.Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3305-20. doi: 10.1158/1055-9965.EPI-09-1014. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19959678 Free PMC article. Review.
-
Characterising the nicotine metabolite ratio and its association with treatment choice: A cross sectional analysis of Stop Smoking Services in England.Sci Rep. 2017 Dec 14;7(1):17613. doi: 10.1038/s41598-017-17994-8. Sci Rep. 2017. PMID: 29242560 Free PMC article.
-
Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different analytical methods and laboratories: implications for clinical implementation.Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1239-46. doi: 10.1158/1055-9965.EPI-14-1381. Epub 2015 May 26. Cancer Epidemiol Biomarkers Prev. 2015. PMID: 26014804 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources